# Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

> **NCT01627041** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 178 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Adult Acute Basophilic Leukemia
- Adult Acute Monoblastic Leukemia
- Adult Acute Monocytic Leukemia
- Adult Acute Myeloid Leukemia With Maturation
- Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A
- Adult Acute Myeloid Leukemia Without Maturation
- Adult Acute Myelomonocytic Leukemia
- Alkylating Agent-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01627041
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-09-16
- **Primary completion:** 2016-02-11
- **Final completion:** 2027-02-01
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627041, "Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01627041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*